8OYU

Stabilised BA.1 SARS-CoV-2 spike with H6 nanobodies in '2 up 1 down' RBD conformation

これはPDB形式変換不可エントリーです。

8OYU の概要

• エントリーDOI: 10.2210/pdb8oyu/pdb
• EMDBエントリー: 17296
• 分子名称: Spike glycoprotein,Fibritin, H6 nanobody, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total)
• 機能のキーワード: nanobody, complex, sars-cov-2, spike, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2; 詳細
• タンパク質・核酸の鎖数: 5
• 化学式量合計: 453656.75

構造登録者

Weckener, M.,Naismith, J.H.,Owens, R.J. (登録日: 2023-05-05, 公開日: 2024-05-15, 最終更新日: 2024-10-16)

主引用文献

Cornish, K.,Huo, J.,Jones, L.,Sharma, P.,Thrush, J.W.,Abdelkarim, S.,Kipar, A.,Ramadurai, S.,Weckener, M.,Mikolajek, H.,Liu, S.,Buckle, I.,Bentley, E.,Kirby, A.,Han, X.,Laidlaw, S.M.,Hill, M.,Eyssen, L.,Norman, C.,Le Bas, A.,Clarke, J.,James, W.,Stewart, J.P.,Carroll, M.,Naismith, J.H.,Owens, R.J.
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
Open Biology, 14:230252-230252, 2024

PubMed Abstract: The Omicron strains of SARS-CoV-2 pose a significant challenge to the development of effective antibody-based treatments as immune evasion has compromised most available immune therapeutics. Therefore, in the 'arms race' with the virus, there is a continuing need to identify new biologics for the prevention or treatment of SARS-CoV-2 infections. Here, we report the isolation of nanobodies that bind to the Omicron BA.1 spike protein by screening nanobody phage display libraries previously generated from llamas immunized with either the Wuhan or Beta spike proteins. The structure and binding properties of three of these nanobodies (A8, H6 and B5-5) have been characterized in detail providing insight into their binding epitopes on the Omicron spike protein. Trimeric versions of H6 and B5-5 neutralized the SARS-CoV-2 variant of concern BA.5 both and in the hamster model of COVID-19 following nasal administration. Thus, either alone or in combination could serve as starting points for the development of new anti-viral immunotherapeutics.

PubMed: 38835241
DOI: 10.1098/rsob.230252

実験手法

ELECTRON MICROSCOPY (4 Å)